Skip to main content

Table 2 Clinical and pathological Characteristics for Eligible Patients in the TCGA Cohort

From: Magnetic resonance imaging and molecular features associated with tumor-infiltrating lymphocytes in breast cancer

Parameter

≤ 10% stromal TILs

> 10 to ≤ 40% stromal TILs

> 40 to ≤ 90% stromal TILs

P valuea

Tumor with no/minimal immune cells (n = 92, 73%)

Tumor with intermediate/heterogeneous infiltrate (n = 25, 20%)

Tumor with high immune infiltrate (n = 9, 7%)

Age, years

 Median (range)

52 (29–82)

56 (38–75)

61 (47–77)

 

 Mean ± SD

52.8 ± 11.6

55.8 ± 11.1

61.2 ± 8.7

 

T

 T1

37 (71)

10 (19)

5 (10)

0.821

 T2

47 (65)

15 (23)

3 (5)

0.744

 T3

8 (89)

0

1 (11)

0.307

N

 N0

44 (69)

16 (25)

4 (6)

0.726

 N1

32 (74)

8 (19)

3 (7)

1

 N2

9 (82)

1 (9)

1 (9)

0.748

 N3

6 (86)

0

1 (14)

0.290

 Nxb

1 (100)

0

0

 

M

 M0

79 (75)

20 (19)

6 (6)

0.919

 Mxc

13 (62)

5 (24)

3 (14)

0.361

Stage

 I

22 (73)

6 (20)

2 (7)

1

 II

53 (70)

18 (24)

5 (7)

0.826

 III

17 (85)

1 (5)

2 (10)

0.204

Histological type

 Invasive ductal carcinoma

80 (75)

19 (18)

7 (7)

0.921

 Invasive lobular carcinoma

10 (59)

5 (29)

2 (12)

0.371

 Other

2 (67)

1 (33)

0

 

Estrogen receptor status

 Positive

79 (75)

19 (18)

7 (7)

0.947

 Negative

13 (62)

6 (29)

2 (10)

0.560

Progesterone receptor status

 Positive

71 (76)

16 (17)

6 (6)

0.888

 Negative

21 (64)

9 (27)

3 (9)

0.515

Human epidermal growth factor receptor 2 status

 Positive

14 (61)

6 (26)

3 (13)

0.384

 Negative

76 (76)

19 (19)

5 (5)

0.790

 Equivocal

2 (67)

0

1 (33)

 

IHC subtype

 HR+/HER2−

68 (78)

14 (16)

5 (6)

0.824

 HER2+

14 (61)

6 (26)

3 (13)

0.571

 ER−/PR−/HER2−

10 (63)

5 (31)

1 (6)

0.592

PAM50 intrinsic subtype

 Luminal A

53 (75)

13 (18)

5 (7)

0.966

 Luminal B

22 (79)

4 (14)

2 (7)

0.875

 HER2

4 (50)

3 (38)

1 (12)

0.219

 Basal

10 (63)

5 (31)

1 (6)

0.536

 Normal

3 (100)

0

0

 
  1. Abbreviations: ER Estrogen receptor, HER2 Human epidermal growth factor receptor 2, HR Hormone receptor, PR Progesterone receptor, TIL Tumor-infiltrating lymphocyte
  2. aFisher’s exact test was used to compare TIL distribution within selected category with TIL distribution of whole population
  3. bLymph node stage is not available
  4. cMetastasis cannot be measured